Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation) (EPIPOD)

February 20, 2020 updated by: Nantes University Hospital
Neonatal nutritional management consists in reproducing miming uteri growth kinetic. Since the seventies, NICU (Neonatal Intensive Care Unit) strategy consists in a high proteidic input (apport) supposed to allow optimal neurodevelopment. However, nutritional practices and strategies have significantly evolved during these last years, influenced by Baker nutritional imprinting concept (2002). Actually, neonatal high proteidic exposition could perturb metabolism and hormonal systems of newborns conducting to a reinforcement of obesity and cardio-vascular pathology prevalence in this target population at adulthood. In this context many studies emerged since 2000 and try to assess the trade-off between neurodevelopment and growth under nutrition conditions. EPIPOD try to focus the link between heterogenous proteic input dispensed in our NICU (described by tercil methods on population) and fat mass phenotype variations at discharge (described by tercil methods); and its consequences on neurodevelopmental growth. Understanding how particular nutritional exposition could determine "fatty" phenotype and impact neurodevelopment is clearly our main goal.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

270

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nantes, France, 44093
        • Nantes University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 8 months (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Preterm infants (< 35 weeks gestation)

Description

Inclusion Criteria:

  • Preterm newborns (< 35 weeks gestation).
  • Final clinical discharge (No transfer)
  • Oral Parental consent.
  • Nantes NICU Neonatal management in the first 5 days of life

Exclusion Criteria:

  • Congenital pathology inconsistent with PEAPOD investigation (Beckwith-Wiedemann syndrome, lipodystrophia with abnormal constitutional fat mass level).
  • Pathology inducing neurodevelopment troubles.
  • Transfer in an other hospital before discharge
  • Hemodynamic or cardiovascular instability requiring continuous monitoring or perfusion, incompatible with PEAPOD measurement

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
preterm infants (<35 weeks gestation)

EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.

After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fatty mass percentage at discharge by PEAPOD measurement
Time Frame: PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assesmment at 2 years old).
PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
Children neurological development at 2 years old evaluated by Ages and stages questionnaires (ASQ)
Time Frame: ASQ/BLR Neurodevelopmental assesmment at 2 years old.
ASQ/BLR Neurodevelopmental assesmment at 2 years old.

Secondary Outcome Measures

Outcome Measure
Time Frame
body composition of preterm infants at discharge and full term newborns at 3 days of life
Time Frame: PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
Relationship between body composition at discharge and that at 2 years
Time Frame: PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
Impact of fatty mass percentage at preterm newborns discharge on neurologic outcome assessed by a revised Brunet-Lezine test at 2 years.
Time Frame: PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
PEAPOD measurement will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
Preterm infants feeding behavior at 2 years
Time Frame: At 2 years old
At 2 years old
Factors (both intrinsic and nutritional) influencing body composition of preterm infants (<35 weeks gestation), at discharge
Time Frame: factors influencing body composition report will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization
factors influencing body composition report will be done at newborns discharge, at an expected average of 6.4 weeks hospitalization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: FRONDAS-CHAUTY Anne, MD, Nantes University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (ACTUAL)

October 1, 2014

Study Completion (ACTUAL)

October 1, 2014

Study Registration Dates

First Submitted

September 28, 2011

First Submitted That Met QC Criteria

October 11, 2011

First Posted (ESTIMATE)

October 12, 2011

Study Record Updates

Last Update Posted (ACTUAL)

February 21, 2020

Last Update Submitted That Met QC Criteria

February 20, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • PROG/11/80

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Other Preterm Infants

Clinical Trials on Peapod assessment

Subscribe